Fund managers have forecast an M&A boom for the biotech sector following Donald Trump's win in the US Presidential Election, but have warned of future uncertainty for wider healthcare services companies in areas such as Obamacare.
In the 24 hours following the US election result, healthcare and biotech-focused investment trusts rebounded after facing significant headwinds in the run-up to the vote, as the Nasdaq Biotechnology index...
The outperformance of emerging markets that began in January 2016 and extended through the rest of that year and 2017 has continued in the first months of 2018. Perhaps the most important driver behind this sustained strength - the first consecutive years...
Threat of trade war escalating
Following investor ‘criticism’
A question of selectivity
'Impress on senior management the importance of diversity’